Base edited “universal” donor CAR T cell strategies for acute myeloid leukaemia
Authors:
Preprint
Abstract
Acute myeloid leukaemia (AML) is often aggressive and life-threatening with limited curative options. Immunotherapies including chimeric antigen receptor (CAR) T cell approaches are under investigation, but high levels of disease heterogeneity remain a major hurdle to achieving durable responses. Targeting of multiple surface antigens may ensure complete immunological coverage of leukemic blast populations, but such antigens are often also present on healthy haematopoietic populations. To address likely aplasia, strategies can be designed to bridge CAR T cell therapies to allogeneic stem cell transplantation (allo-SCT), as demonstrated in recent anti-CD7 CAR T cell studies. Here we report that monotherapy using base edited (BE) ‘universal’ donor CAR T cells against CD33, CLL-1, or CD7 delivered inhibition of AML in immunodeficient mice when antigen expression was homogenous, but combined use of BE-CAR33 and BE-CARCLL-1 T cells was required to address heterogenous CLL-1 -/+ CD33 -/+ disease. We also demonstrate that removal of shared CD7 antigens enabled compatibility of BE-CAR33 with BE-CAR7 T cells, including in a patient-derived xenograft (PDX) model of AML. Therapeutic strategies envisage ‘pick and mix’ applications of base edited universal CAR T cells in combinations determined by patient-specific antigen profiles. Such approaches also offer the possibility of deep, cell-based, de-bulking and preparative conditioning ahead of allo-SCT followed by donor-derived reconstitution.Keywords
All Related Versions
- Published version: Leukemia, 39 (12), 2978.
This publication has 39 references indexed in Scilit:
- Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancyCytotherapy, 2021
- Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemiaLeukemia, 2021
- Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AMLLeukemia, 2018
- Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic EffectsMolecular Therapy, 2018
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemiaLeukemia, 2015
- Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid LeukemiaMolecular Therapy, 2015
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trialsThe Lancet Oncology, 2014
- Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid LeukemiaCancer Cell, 2014
- AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemiaCancer, 2011
- Human MICL (CLEC12A) is differentially glycosylated and is down‐regulated following cellular activationEuropean Journal of Immunology, 2006